MedTrace Logo

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

NCT01671332 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-05-12

Study results available
· View outcomes & findings →

Summary

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

Docetaxel

IV over 60 minutes, 75 mg/m2

DRUG

Suramin

IV over 30 minutes

DRUG

Docetaxel

IV over 60 minutes. 56 mg/m2

Sponsors & Collaborators

  • Medical College of Wisconsin

    collaborator OTHER

  • Optimum Therapeutics, LLC

    collaborator INDUSTRY

  • Ohio State University

    collaborator OTHER

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Anne M Traynor, MD · University of Wisconsin, Madison

  • Rafael Santana-Davila, MD · Medical College of Wisconsin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-06-11
Completion
2016-06-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01671332 on ClinicalTrials.gov